Wishing you a year filled with health, happiness, peace, and prosperity. CHEERS! #HappyNewYear2025!
Castle Biosciences, Inc.
Biotechnology Research
Friendswood, Texas 13,312 followers
Improving health through innovative tests that guide patient care
About us
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, mental health and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. IDgenetix is Castle's pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient’s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
- Website
-
https://castlebiosciences.com/
External link for Castle Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Friendswood, Texas
- Type
- Public Company
- Founded
- 2008
- Specialties
- Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma, Gene Expression Profile Tests, Barrett's Esophagus, Esophageal Adenocarcinoma, and Dermatologic Cancer
Locations
-
Primary
Get directions
505 S Friendswood Dr
Suite 401
Friendswood, Texas 77546, US
-
Get directions
3737 N 7th St
Suite 160
Phoenix, Arizona 85014, US
-
Get directions
235 William Pitt Way
B1
Pittsburgh, Pennsylvania 15238, US
Employees at Castle Biosciences, Inc.
Updates
-
Castle announces an update to its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking systemic treatment. Based on preliminary data from the ongoing prospective development and validation study, Castle’s pipeline test has shown potential to identify a subset of patients with AD who have an increased likelihood to achieve a super response to targeted therapies...(more): https://hubs.la/Q030wfKb0
-
-
Read about TissueCypher — A Game-Changing Test in the Fight Against Esophageal Cancer — on page 10...
🌟 Our Digestive Health & Diseases Campaign Has Launched! 🌟 This campaign explores the latest advancements in digestive care, highlights expert insights, and provides actionable information to help individuals better understand and manage their gut health. From prevention and early diagnosis to cutting-edge treatment options, we’re shining a light on the importance of digestive health for everyone. Check out the full campaign here: https://lnkd.in/eFSJ_XtV Thank you to our partners! VIVUS LLC Castle Biosciences, Inc. Iterative Health Takeda Guardant Health Exact Sciences Medtronic Olympus Corporation Salix Pharmaceuticals Herbalife American Liver Foundation American Gastroenterological Association (AGA) Colorectal Cancer Alliance GI Alliance Dr Megan Rossi Amway
-
Castle Biosciences' TissueCypher® test can offer patients with Barrett's esophagus a clearer picture of their risk of developing esophageal cancer, which is the 8th most common form of cancer worldwide and the 6th leading cause of cancer death (due in part to late diagnoses). Learn more about how TissueCypher can help (via USA TODAY and Mediaplanet USA): https://lnkd.in/gMBycc73
-
Throughout November, Castle employees halted their activity of choice (much in the spirit of No-Shave November) and raised money for their chosen charity. 53 #TeamCastle members got creative — no negativity, no missed workouts, no slacking, no junk food, no hitting snooze, and of course, no shaving, just to name a few — and together, raised $5,645 for 18 organizations. Cheers to all the No ___ November participants! #CastleCulture #CastleCares
-
-
It was a great weekend for the Fort Myers Miles for Melanoma 5K! #TeamCastle was proud to support the Melanoma Research Foundation, helping them reach 111% of their $40,000 goal towards eradicating melanoma. Camilla Zuckero and MaryAdelle Barry representing.
-
-
A new independent meta-analysis was published in Cancers assessing the efficacy of the DecisionDx-Melanoma test in predicting melanoma patient outcomes. The article, titled “The Prognostic Value of the 31-Gene Expression Profile Test in Cutaneous Melanoma: A Systematic Review and Meta-Analysis,” concluded that DecisionDx-Melanoma consistently provides improved risk stratification over staging alone to inform personalized management strategies for patients with cutaneous melanoma (CM). The meta-analysis encompasses 13 peer-reviewed publications involving thousands of patients and affirms the powerful risk stratification provided by DecisionDx-Melanoma and its potential to significantly improve care for patients with CM. Highlights: https://hubs.ly/Q02_DBKl0
-
-
We are beyond excited to bring home EIGHT multi-year #TopWorkplaces Culture Excellence awards in 2024! #CastleCulture was honored for #EmployeeAppreciation, #Compensation & #Benefits, #EmployeeWellBeing, #Innovation, #Leadership, #ProfessionalDevelopment, #Purpose & #Values, and #WorkLifeFlexibility.
-
-
Castle Biosciences, Inc. reposted this
Shout out to Castle Biosciences and their commitment to #melanoma awareness programs in Massachusetts, Texas, and Arizona. 💪💛 We’re proud to partner with a company that supports our mission. Read more about their role as a #PartnerInPrevention: https://bit.ly/3vvAMCn #PartnerinPrevention #IMPACTMelanoma
-